Bavarian Nordic Secures 440,000 Dose Contract for Smallpox and Mpox Vaccines in Europe

Bavarian Nordic A/S, headquartered in Copenhagen, Denmark, announced on August 21, 2024, the receipt of a contract to supply 440,000 doses of its MVA-BN® smallpox and mpox vaccine to a European country that remains undisclosed. This order was expected as part of the company's 2024 guidance and does not affect the remaining 2024/25 production capacity for the smallpox and mpox vaccine.

Paul Chaplin, the President and CEO of Bavarian Nordic, remarked on the establishment of strategic partnerships with various authorities since the last mpox outbreak in 2022/23. These authorities have recognized the importance of being prepared for smallpox and mpox incidents. The latest order aligns with the company's original projections for the year and will not impact the available capacity for supporting governments and organizations currently addressing the World Health Organization’s Public Health Emergency of International Concern for mpox. Bavarian Nordic is positioned to supply up to 10 million doses of the smallpox and mpox vaccine by the end of 2025, with 2 million doses available within the remaining part of 2024.

The vaccine deliveries under this contract are scheduled for 2024, bringing the total value of secured contracts in Bavarian Nordic’s Public Preparedness business close to DKK 3,000 million. This figure represents the higher end of the company's revenue guidance for this segment in 2024. Consequently, the company has updated its annual guidance to reflect an aggregated revenue of approximately DKK 5,300 million and an EBITDA of around DKK 1,350 million.

Breaking down the total projected revenue of DKK 5,300 million, around DKK 3,000 million is expected from Public Preparedness, DKK 2,100 million from Travel Health, and approximately DKK 200 million from contract work.

The MVA-BN vaccine, also known under brand names such as JYNNEOS®, IMVANEX®, and IMVAMUNE®, is a non-replicating vaccine for smallpox and mpox. It has received approval from regulatory agencies including the FDA, the European Commission, Health Canada, the UK's MHRA, and Swissmedic. Moreover, it has been granted emergency use authorization in various territories during the mpox outbreak. The vaccine was initially developed in collaboration with the U.S. government to ensure a secure supply of smallpox vaccines, particularly for immunocompromised individuals who are not suited for traditional replicating smallpox vaccines.

Bavarian Nordic is a fully integrated vaccine company dedicated to protecting and saving lives through innovative vaccines. The company is a global leader in smallpox and mpox vaccines, supplying these to governments to improve public health preparedness. Additionally, Bavarian Nordic boasts a robust portfolio of vaccines for travelers and endemic diseases.